Norm M. Greenberg, PhD
Dr. Greenberg is Senior Vice President at Checkmate Pharmaceuticals. Prior to that, he served as Senior Vice President of Research at MedImmune (Astra Zeneca), Senior Director of Oncology at Pfizer, and Professor at Fred Hutchinson Cancer Research Center. Dr. Greenberg has over 25 years’ professional experience as a scientist, drug researcher, and developer and has directed innovative research programs in academia and industry, including important leading-edge therapies in immunotherapy, immuno-oncology (eg, 41BB, CTLA4, PD-L1, OX40), tumor-targeted therapies, and antibody-drug conjugates.
Craig W. Philips. BS, MBA
Mr. Philips has been a leader in the biopharmaceutical industry for over 25 years and has extensive experience in business development, commercialization of new drugs, and lifecycle management. He has previously served in a number of leadership roles, including Executive Vice President of Commercial Operations and President of Kineta, Inc.; President of Cell therapeutics, Inc.; Vice President and General Manager of Bayer Oncology; Vice President and General Manager of Berlex Biosciences; and several others. Mr. Philips currently serves as Chief Operating Officer at KPI Therapeutics.
Cassian Yee, MD
Dr. Yee holds multiple positions at the University of Texas MD Anderson Cancer Center, including Professor of Melanoma Medical Oncology in the Division of Cancer Medicine and Director of Solid Tumor Cell Therapy at the Center for Cancer Immunology Research. Dr. Yee has pioneered many innovative technologies for enhancing cell-based cancer immunotherapy. He is also a member of the scientific research team at Stand Up To Cancer (SU2C). Dr. Yee received his medical degree from the University of Manitoba in Canada and trained as a research fellow at the Ontario Cancer Institute in Toronto before continuing his medical residency at Stanford University and fellowships in medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center.